Get the Stockscreener App
27.00
7.22%
-2.10
After Hours:
26.79
-0.21
-0.78%
Janux Therapeutics Inc stock is traded at $27.00, with a volume of 910.99K.
It is down -7.22% in the last 24 hours and down -17.91% over the past month.
See More
Previous Close:
$29.10
Open:
$28.13
24h Volume:
910.99K
Relative Volume:
1.03
Market Cap:
$1.76B
Revenue:
$13.05M
Net Income/Loss:
$-60.54M
P/E Ratio:
-23.28
EPS:
-1.16
Net Cash Flow:
$-37.82M
1W Performance:
-14.93%
1M Performance:
-17.91%
6M Performance:
-40.57%
1Y Performance:
-28.29%
1-Day Range:
$26.39
$28.13
1-Week Range:
$26.39
$32.00
52-Week Range:
$26.39
$71.71
Janux Therapeutics Inc Stock (JANX) Company Profile
Name
Janux Therapeutics Inc
Sector
Industry
Phone
(858) 751-4493
Address
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
Compare JANX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JANX
Janux Therapeutics Inc
|
27.00 | 1.76B | 13.05M | -60.54M | -37.82M | -1.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-03-24 | Reiterated | BTIG Research | Buy |
| Dec-03-24 | Reiterated | H.C. Wainwright | Buy |
| Nov-22-24 | Initiated | Leerink Partners | Outperform |
| Oct-24-24 | Initiated | UBS | Buy |
| Sep-06-24 | Initiated | Stifel | Buy |
| May-30-24 | Initiated | Scotiabank | Sector Perform |
| Mar-21-24 | Initiated | BTIG Research | Buy |
| Mar-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-06-23 | Initiated | Wedbush | Outperform |
| Nov-14-22 | Initiated | William Blair | Outperform |
View All
Janux Therapeutics Inc Stock (JANX) Latest News
Janux Therapeutics stock hits 52-week low at $28.92 By Investing.com - Investing.com South Africa
Janux Therapeutics stock hits 52-week low at $28.92 - Investing.com India
Is Janux Therapeutics Inc. (NASDAQ:JANX) the Best Up and Coming Stock to Buy According to Wall Street Analysts? - Yahoo Finance
Is Janux Therapeutics, Inc. (NASDAQ:JANX) the Best Small Cap Stock to Buy Before They Explode? - Insider Monkey
Janux Therapeutics, Inc. (JANX): Among Stocks Receiving the Most Insider Love in March - MSN
We're Interested To See How Janux Therapeutics (NASDAQ:JANX) Uses Its Cash Hoard To Grow - Yahoo Finance
12 Best Up and Coming Stocks to Buy According to Wall Street Analysts - Insider Monkey
First Week of JANX November 21st Options Trading - Nasdaq
RA Capital Management, L.P. Increases Stake in Janux Therapeutics Inc - GuruFocus.com
Insiders Are Spending Big: 15 Stocks Leading in March - Insider Monkey
Is Janux Therapeutics (JANX) a Worst High-Risk High-Reward Growth Stock to Buy? - Insider Monkey
10 Worst High-Risk High-Reward Growth Stocks To Buy - Insider Monkey
Commit To Buy Janux Therapeutics At $25, Earn 30% Annualized Using Options - Nasdaq
Biotech Alert: Searches spiking for these stocks today - Yahoo Finance
EGFR Non-Small Cell Lung Cancer Clinical and Non-Clinical - openPR
Janux Therapeutics (NASDAQ:JANX) Shares Gap Up Following Insider Buying Activity - Defense World
Insiders Are Loading Up on These 4 Biotech Stocks Now - 24/7 Wall St.
(JANX) Proactive Strategies - news.stocktradersdaily.com
JANX stock touches 52-week low at $29.62 amid market shifts By Investing.com - Investing.com South Africa
JANX stock touches 52-week low at $29.62 amid market shifts - Investing.com India
Sunday Insider Moves: Top Buys and Sells from Friday’s Disclosures By Investing.com - Investing.com Australia
Sunday Insider Moves: Top Buys and Sells from Friday’s Disclosures - Investing.com India
Ra Capital Management, L.P. Purchases 341,742 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) Stock - Defense World
Ra Capital Management, L.P. Purchases 110,206 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) Stock - Defense World
Major Investment Alert: Janux Therapeutics Stock Sees Massive Buy-In! - TipRanks
Proficio Capital Partners LLC Invests $1.35 Million in Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World
Ra capital management buys $25.3 million in Janux therapeutics stock By Investing.com - Investing.com Australia
Ra capital management buys $25.3 million in Janux therapeutics stock - Investing.com
HC Wainwright Has Pessimistic Outlook of JANX Q1 Earnings - Defense World
Janux Therapeutics (JANX) Projected to Post Quarterly Earnings on Friday - Defense World
Janux Therapeutics chief business officer sells shares for $107,174 By Investing.com - Investing.com South Africa
Janux Therapeutics, Inc. (NASDAQ:JANX) Given Consensus Rating of “Buy” by Brokerages - Defense World
Janux Therapeutics chief business officer sells shares for $107,174 - Investing.com India
Janux Therapeutics, Inc. (JANX): Among The Stocks With At Least $30 Million In Insider Spending Recently - Insider Monkey
JANUX THERAPEUTICS Earnings Preview: Recent $JANX Insider Trading, Hedge Fund Activity, and More - Nasdaq
10 Stocks With At Least $30 Million In Insider Spending Recently - Insider Monkey
Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Acquired by Rhumbline Advisers - Defense World
Janux Therapeutics, Inc. (NASDAQ:JANX) Stock Holdings Lifted by New York State Common Retirement Fund - Defense World
Janux Therapeutics (NASDAQ:JANX) Given “Buy” Rating at HC Wainwright - Defense World
Janux Therapeutics (NASDAQ:JANX) Sets New 52-Week Low on Analyst Downgrade - Defense World
Promising Developments and Strong Financial Position Support Buy Rating for Janux Therapeutics - TipRanks
Janux Therapeutics’ (JANX) Outperform Rating Reiterated at Wedbush - Defense World
Positive Outlook for Janux Therapeutics Inc. Driven by Unique Therapeutic Potential and Strategic Advantages - TipRanks
Janux Therapeutics price target lowered to $41 from $62 at Scotiabank - Yahoo Finance
Janux Therapeutics Reports Strong Financial Position and Clinical Progress - TipRanks
Janux Therapeutics (NASDAQ:JANX) Announces Quarterly Earnings Results, Beats Estimates By $0.13 EPS - MarketBeat
Analyst Recommends ‘Buy’ for Janux Therapeutics Inc. Amid Share Price Decline and Promising Clinical Outlook - TipRanks
Janux Therapeutics Inc Stock (JANX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.05%
1.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):